DRUG-INDUCED HYPOTHYROIDISM Drug-Induced Primary
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hashimoto's Thyroiditis
AMERICAN THYROID ASSOCIATION® www.thyroid.org Hashimoto’s Thyroiditis (Lymphocytic Thyroiditis) WHAT IS THE THYROID GLAND? HOW IS THE DIAGNOSIS OF HASHIMOTO’S The thyroid gland is a butterfly-shaped endocrine gland THYROIDITIS MADE? that is normally located in the lower front of the neck. The diagnosis of Hashimoto’s thyroiditis may be made The thyroid’s job is to make thyroid hormones, which are when patients present with symptoms of hypothyroidism, secreted into the blood and then carried to every tissue often accompanied by a goiter (an enlarged thyroid in the body. Thyroid hormones help the body use energy, gland) on physical examination, and laboratory testing of stay warm and keep the brain, heart, muscles, and other hypothyroidism, which is an elevated thyroid stimulating organs working as they should. hormone (TSH) with or without a low thyroid hormone (Free WHAT IS HASHIMOTO’S THYROIDITIS? thyroxine [Free T4]) levels. TPO antibody, when measured, is usually elevated. The term “Thyroiditis” refers to “inflammation of the thyroid gland”. There are many possible causes of thyroiditis (see Occasionally, the disease may be diagnosed early, Thyroiditis brochure). Hashimoto’s thyroiditis, also known especially in people with a strong family history of thyroid as chronic lymphocytic thyroiditis, is the most common disease. TPO antibody may be positive, but thyroid cause of hypothyroidism in the United States. It is an hormone levels may be normal or there may only be autoimmune disorder involving chronic inflammation of isolated mild elevation of serum TSH is seen. Symptoms of the thyroid. This condition tends to run in families. Over hypothyroidism may be absent. -
(12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al
US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012. -
Thyroid Disease in the Perinatal Period
Thyroid Thyroid disease in Simon Forehan the perinatal period Background Thyroid dysfunction affects 2–3% of pregnant women and Thyroid hormone plays a critical role in fetal development. In one in 10 women of childbearing age with normal thyroid pregnancy, increased thyroid hormone synthesis is required to function have underlying thyroid autoimmunity, which may meet fetal needs, resulting in increased iodine requirements. indicate reduced functional reserve.1 Up to 18% of women in Objective the first trimester in Australia are thyroid antibody positive.2 This article outlines changes to thyroid physiology and Thyroid hormone plays a critical role in pregnancy and iodine requirements in pregnancy, pregnancy specific understanding the unique changes to thyroid physiology in reference ranges for thyroid function tests and detection and pregnancy has important implications for the definition and management of thyroid conditions in pregnancy. treatment of thyroid disorders in pregnancy. Discussion Thyroid dysfunction affects 2–3% of pregnant women. Pregnancy specific reference ranges are required to define Thyroid physiology and pregnancy thyroid conditions in pregnancy and to guide treatment. The fetus is dependent on transplacental transfer of maternal thyroxine Overt maternal hypothyroidism is associated with adverse (T4). Deiodination of maternal T4 by the fetus results in local fetal pregnancy outcomes; thyroxine treatment should be production of liothyronine (T3), which is particularly important for commenced immediately in this condition. Thyroxine neurological development.3,4 Maternal T3 does not cross the placenta treatment has also been shown to be effective for pregnant and appears to have little, if any, role in development. Other changes in women with subclinical hypothyroidism who are thyroid pregnancy include an increase in thyroid binding globulin (TBG), resulting peroxidase antibody positive. -
NO-1886 Decreases Ectopic Lipid Deposition and Protects Pancreatic Cells in Diet-Induced Diabetic Swine
399 NO-1886 decreases ectopic lipid deposition and protects pancreatic cells in diet-induced diabetic swine W Yin*,1,2,5, D Liao*,1,2, M Kusunoki6,SXi1, K Tsutsumi3, Z Wang1, X Lian1, T Koike4, J Fan4, Y Yang5 and C Tang5 1Department of Biochemistry and Biotechnology, Nanhua University School of Life Sciences and Technology, Hengyang, Hunan 421001, China 2Department of Pathophysiology, Central South University Xiangya Medical College, Changsha, Hunan, China 3Research and Development, Otsuka Pharmaceutical Factory Inc., Tokushima, Japan 4Laboratory of Cardiovascular Disease, Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba 305-8575, Japan 5Institute of Cardiovascular Research, Nanhua University Medical School, Hengyang, Hunan 421001, China 6Department of Internal Medicine, Faculty of Medicine, Aichi Medical University, Nagakute-cho, Aichigunte, Aichi 480-11, Japan (Requests for offprints should be addressed to W Yin, Department of Biochemistry and Molecular Biology, Nanhua University School of Life Sciences and Technology, Hengyang, Hunan 421001, China; Email: [email protected]) *W Yin and D Liao contributed equally to this paper Abstract The synthetic compound NO-1886 (ibrolipim) is a lipo- skeletal muscle, liver and pancreas, and also caused pan- protein lipase activator that has been proven to be highly creatic cell damage. However, supplementing 1% NO- effective in lowering plasma triglycerides. Recently, we 1886 (200 mg/kg per day) into the high-fat/high-sucrose found that NO-1886 also reduced plasma free fatty acids diet decreased ectopic lipid deposition, improved insulin and glucose in high-fat/high-sucrose diet-induced dia- resistance, and alleviated the cell damage. These results betic rabbits. -
Study Protocol C31002 Protocol a M End Ment 2
Title: Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors NCT Number: NCT02197572 Protocol Approve Date: 28 November 2017 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information (PPD) or company confidential information (CCI). This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. M L N 0 1 2 8 Clinical Study Protocol C31002 Protocol A m end ment 2 CLINICAL STUDY PROTOCOL C31002 PROTOCOL A MEND MENT 2 M L N 0 1 2 8 A P h as e 1 St u d y t o E v al u at e t h e Eff e ct of M L N 0 1 2 8 o n t h e Q T c I nt er v al i n P ati e nts Wit h Advanced Solid Tu mors Protocol Nu mber: C 3 1 0 0 2 Indication: Ad vanced solid tu mors P h as e: 1 S p o ns o r: Mill e n ni u m P h ar m a c e uti c als, I n c. Eudra CT Nu mber: N ot a p pli c a bl e Therapeutic Area: O n c o l og y Protocol History Ori gi n al 29 October 2013 Protocol A mend ment 1 26 June 2014 Protocol A mend ment 2 28 Nove mber 2017 Mill e n ni u m P h ar m a c e uti c als, I n c. -
Ct Scan- Upper and Lower Extremities
CT SCAN- UPPER AND LOWER Smithfield Imaging 919-938-7190 Clayton Imaging 919-585-8450 EXTREMITIES Scheduling 919-938-7449 WHAT IS A CT SCAN OF THE UPPER AND LOWER EXTREMITIES? Extremity CT scans are taken of the bones and soft tissue of the following: arms, legs, hips, pelvis, feet, ankles, wrists, and shoulders. These CT images are far more detailed than those obtained from conventional x-rays. The scan is also used as a diagnostic tool because of its ability to display different types of tissue in the same region, including bone, muscle, soft tissue, and blood vessels. These scans evaluate for unexplained pain or swelling, trauma, a known mass, infection and questionable fractures. HOW IT WORKS Your physician may order this test with or without a contrast agent depending on your diagnosis. If contrast material is used, it will be injected through an intravenous line (IV). The contrast is an iodinated contrast so please inform the technologist if you are allergic to iodine or any type of contrast agent. Please inform the technologist if you are pregnant. Many imaging tests are not preformed during pregnancy. Please be advised of the following information before receiving any contrast agent. If you have ever had an allergic reaction to any contrast agent, you may require a steroid prep the day before the test. Please consult your physician in regards to the steroid prep. If you are age 40 or older or a diabetic; you will need labs drawn prior to your contrasted exam. Please consult your physician in regards to these labs. -
Download the Final Guidance Document
Guidance for Industry: New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products Additional copies are available from: Office of Combination Products, HFG-3 Office of the Commissioner Food and Drug Administration 15800 Crabbs Branch Way Rockville, MD 20855 (Tel) 301-427-1934 (Fax) 301-427-1935 http://www.fda.gov/oc/combination U.S. Department of Health and Human Services Food and Drug Administration Office of Combination Products (OCP) in Office of the Commissioner Center for Devices and Radiological Health (CDRH) Center for Drug Evaluation and Research (CDER) December 2009 Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 3 II. SCOPE ............................................................................................................................... 4 III. TERMINOLOGY ............................................................................................................. 4 IV. BACKGROUND ............................................................................................................... 5 V. GENERAL PRINCIPLES ............................................................................................... 6 VI. WHAT TYPE OF MARKETING SUBMISSION TO PROVIDE............................. 10 VII. ILLUSTRATIONS FOR WHEN A DEVICE SUBMISSION (510(K) OR PMA) IS SUFFICIENT AND AN NDA SUBMISSION IS NOT NECESSARY ...................... 12 VIII. ILLUSTRATIONS -
MFM Clinical Guideline
MFM Clinical Guideline Thyroid Disease in Pregnancy Thyroid disease is the 2nd most common endocrinopathy in pregnancy after diabetes. In pregnancy: thyroid volume ↑ 30%, total/bound T3 and T4 levels ↑, but free/unbound T3 and T4 levels are stable due to ↑ thyroid binding globulin. In the 1st trimester, TSH levels ↓ due to high levels of hCG,which directly stimulates the TSH receptor, but return to baseline in the 2nd trimester. TSH does not cross the placenta. Maternal T4 is transferred to the fetus and is important for fetal brain development, especially before the fetal thyroid gland begins to synthesize thyroid hormone at 12-14 weeks. Screening for Thyroid Disease in Pregnancy Table 1: Screening. Table 2: Pregnancy reference ranges. Who to Screen Trimester TSH FT4* Age > 30 1st 0.1 - 2.5 0.8 - 1.2 BMI > 40 mIU/L ng/dL Current signs/symptoms of thyroid dysfunction 2nd 0.2 - 3 mIU/L 0.6 - 1 ng/dL Known positive thyroid antibodies 3rd 0.3 - 3 mIU/L 0.5 - 0.8 ng.dL Goiter *Due to inaccuracy of thyroid testing in pregnancy, Hx head/neck irradiation or thyroid surgery FT4 goal FHx thyroid disease should be the upper half of the reference range Pregestational diabetes Table 3: Interpreting the results. Autoimmune disorders TSH FT4 Hx of pregnancy loss, PTD, infertility Use of amiodarone or lithium, recent administration of Overt Hyperthyroidism ↓ ↑ iodinated radiologic contrast Subclinical ↓ NL Hyperthyroidism Residing in an area of known iodine deficiency Gestational 1st trim: ↓ UL How to Screen Hyperthyroidism 2nd trim: NL/ Step 1: TSH, -
Thyroiditis: an Integrated Approach LORI B
Thyroiditis: An Integrated Approach LORI B. SWEENEY, MD, Virginia Commonwealth University Health System, Richmond, Virginia CHRISTOPHER STEWART, MD, Bayne-Jones Army Community Hospital, Fort Polk, Louisiana DAVID Y. GAITONDE, MD, Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia Thyroiditis is a general term that encompasses several clinical disorders characterized by inflammation of the thyroid gland. The most common is Hashimoto thyroiditis; patients typically present with a nontender goiter, hypothyroid- ism, and an elevated thyroid peroxidase antibody level. Treatment with levothyroxine ameliorates the hypothyroid- ism and may reduce goiter size. Postpartum thyroiditis is transient or persistent thyroid dysfunction that occurs within one year of childbirth, miscarriage, or medical abortion. Release of preformed thyroid hormone into the bloodstream may result in hyperthyroidism. This may be followed by transient or permanent hypothyroidism as a result of depletion of thyroid hormone stores and destruction of thyroid hormone–producing cells. Patients should be monitored for changes in thyroid function. Beta blockers can treat symptoms in the initial hyperthyroid phase; in the subsequent hypothyroid phase, levothyroxine should be considered in women with a serum thyroid-stimulating hormone level greater than 10 mIU per L, or in women with a thyroid-stimulating hormone level of 4 to 10 mIU per L who are symptomatic or desire fertility. Subacute thyroiditis is a transient thyrotoxic state characterized by anterior neck pain, suppressed thyroid-stimulating hormone, and low radioactive iodine uptake on thyroid scanning. Many cases of subacute thyroiditis follow an upper respiratory viral illness, which is thought to trigger an inflammatory destruction of thyroid follicles. In most cases, the thyroid gland spontaneously resumes normal thyroid hormone production after several months. -
Management of Endocrinopathies in Pregnancy: a Review of Current Evidence
International Journal of Environmental Research and Public Health Review Management of Endocrinopathies in Pregnancy: A Review of Current Evidence Daniela Calina 1,† , Anca Oana Docea 2,*,†, Kirill Sergeyevich Golokhvast 3,†, Stavros Sifakis 4, Aristides Tsatsakis 5 and Antonis Makrigiannakis 6 1 Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; [email protected] 2 Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 3 Scientific Education Center of Nanotechnology, Far Eastern Federal University, Vladivostok 690950, Russia; [email protected] 4 Department of Obstetrics and Gynecology, Mitera Maternity Hospital, 71110 Heraklion, Crete, Greece; [email protected] 5 Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71110 Heraklion, Crete, Greece; [email protected] 6 Department of Obstetrics and Gynecology, Medical School, University of Crete, 71110 Heraklion, Crete, Greece; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Received: 28 January 2019; Accepted: 27 February 2019; Published: 4 March 2019 Abstract: Pregnancy in women with associated endocrine conditions is a therapeutic challenge for clinicians. These disorders may be common, such us thyroid disorders and diabetes, or rare, including adrenal and parathyroid disease and pituitary dysfunction. With the development of assisted reproductive techniques, the number of pregnancies with these conditions has increased. It is necessary to recognize symptoms and correct diagnosis for a proper pharmacotherapeutic management in order to avoid adverse side effects both in mother and fetus. This review summarizes the pharmacotherapy of these clinical situations in order to reduce maternal and fetal morbidity. -
Prohibited Substances List
Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). -
Treating Thyroid Disease: a Natural Approach to Healing Hashimoto's
Treating Thyroid Disease: A Natural Approach to Healing Hashimoto’s Melissa Lea-Foster Rietz, FNP-BC, BC-ADM, RYT-200 Presbyterian Medical Services Farmington, NM [email protected] Professional Disclosures I have no personal or professional affiliation with any of the resources listed in this presentation, and will receive no monetary gain or professional advancement from this lecture. Talk Objectives • Define hypothyroidism and Hashimoto’s. • Discuss various tests used to identify thyroid disease and when to treat based on patient symptoms • Discuss potential causes and identify environmental factors that contribute to disease • Describe how the gut (food sensitivities) and the adrenals (chronic stress) are connected to Hashimoto’s and how we as practitioners can work to educate patients on prevention before the need for treatment • How the use of adaptogens can enhance the treatment of Hashimoto’s and identify herbs that are showing promise in the research. • How to use food, exercise, and relaxation to improve patient outcomes. Named for Hakuro Hashimoto, a physician working in Europe in the early 1900’s. Hashimoto’s was the first autoimmune disease to be recognized in the scientific literature. It is estimated that one in five people suffer from an autoimmune disease and the numbers continue to rise. Women are more likely than men to develop an autoimmune disease, and it is believed that 75% of individuals with an autoimmune disease are female. Thyroid autoimmune disease is the most common form, and affects 7-8% of the population in the United States. Case Study Ms. R is a 30-year-old female, mother of three, who states that after the birth of her last child two years ago she has felt the following: • Loss of energy • Difficulty losing weight despite habitual eating pattern • Hair loss • Irregular menses • Joints that ache throughout the day • A general sense of sadness • Cold Intolerance • Joint and Muscle Pain • Constipation • Irregular menstruation • Slowed Heart Rate What tests would you run on Ms.